Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
Affiliation
Univ Arizona, St Josephs Hosp, Coll Med, Sch Med, Arizona Oncol US Oncol NetworkIssue Date
2019-06-07Metadata
Show full item recordPublisher
AMER SOC CLINICAL ONCOLOGYCitation
Del Campo, J. M., Matulonis, U. A., Malander, S., Provencher, D., Mahner, S., Follana, P., ... & Canzler, U. (2019). Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. Journal of Clinical Oncology, JCO-18.Journal
JOURNAL OF CLINICAL ONCOLOGYRights
Copyright © 2019 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
A total of 553 patients were enrolled in the trial. Of 203 patients with a germline BRCA mutation (gBRCAmut), 99 had a PR and 104 had a CR to their last platinum-based therapy; of 350 patients without a confirmed gBRCAmut (non-gBRCAmut), 173 had a PR and 177 had a CR. Post hoc analyses were carried out to evaluate safety and the risk of progression in these patients according to gBRCAmut status and response to their last platinum-based therapy. Ovarian cancer-specific symptoms and quality of life were assessed using the Functional Assessment of Cancer Therapy-Ovarian Symptom Index.Note
Open access articleISSN
0732-183XPubMed ID
31173551Version
Final published versionSponsors
TESARO: A GSK CompanyScopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2019 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License.